Research by Montefiore and Albert Einstein College of Medicine found that Black and Hispanic patients had a higher occurrence of preexisting conditions and higher rates of hospitalization.
(BRONX, NY)—A study from Montefiore Health System and Albert Einstein College of Medicine published today in JAMA Network Open found that among 5902 ethnically diverse coronavirus disease 2019 (COVID-19)–positive patients admitted to Montefiore Medical Center, the outcomes for Black and Hispanic patients relative to their White counterparts were the same or better.
The study shows that Black and Hispanic patients who were hospitalized with COVID-19 presented with more preexisting conditions, also known as comorbidities, as well as other risk factors. However, researchers found that Black and Hispanic patients had survival rates at least as good as their non-Hispanic White counterparts, when controlling for age, sex, socioeconomic status and comorbidities. Similar data trends have been shown in patients hospitalized in other major health systems in Louisiana and the Midwest.
“It is well-documented that communities of color have shouldered the heaviest burden of COVID-19 in the United States, and there have been many explanations offered for why that is the case,” said Andrew D. Racine, MD, PhD, system senior vice president and chief medical officer at Montefiore and professor of pediatrics at Einstein. “We discovered, somewhat surprisingly, that Black and Hispanic patients, when hospitalized, had similar or slightly better survival outcomes compared to White patients.”
Without IRA Fix, COA Warns Community Oncology Practices Will Shut Down
June 30th 2025Ted Okon, MBA, of the Community Oncology Alliance discusses how community oncology faces a revenue crisis due to the Inflation Reduction Act's impact on Medicare reimbursement, risking patient access to vital cancer treatments.
Read More
Many Patients Stop GLP-1s Before Reaching Target Dose: Hamlet Gasoyan, PhD
June 19th 2025Discontinuing the weight loss treatment before hitting the recommended maintenance dose contributes to low-value care despite provider follow-up and efforts to manage side effects, says Hamlet Gasoyan, PhD, Cleveland Clinic.
Read More
AMGA Releases Population Health Framework to Improve ASCVD Secondary Prevention
June 18th 2025Proven interventions to improve care, address disparities, and support lipid management are woven throughout AMGA Foundation's new framework to guide population health–based secondary prevention strategies for atherosclerotic cardiovascular disease (ASCVD).
Read More